Y-mAbs Therapeutics (NASDAQ:YMAB) Stock Price Down 3.3%

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Get Free Report) shares dropped 3.3% on Tuesday . The company traded as low as $13.97 and last traded at $13.97. Approximately 39,904 shares traded hands during trading, a decline of 90% from the average daily volume of 405,209 shares. The stock had previously closed at $14.45.

Wall Street Analysts Forecast Growth

YMAB has been the topic of a number of recent analyst reports. HC Wainwright boosted their target price on shares of Y-mAbs Therapeutics from $21.00 to $22.00 and gave the stock a "buy" rating in a report on Wednesday, March 6th. BMO Capital Markets boosted their target price on shares of Y-mAbs Therapeutics from $16.00 to $26.00 and gave the stock an "outperform" rating in a report on Monday, March 4th. Wedbush reiterated an "outperform" rating and issued a $18.00 price objective (up from $12.00) on shares of Y-mAbs Therapeutics in a report on Monday, February 12th. Finally, Canaccord Genuity Group upped their price objective on shares of Y-mAbs Therapeutics from $22.00 to $26.00 and gave the company a "buy" rating in a report on Monday, March 4th. Two research analysts have rated the stock with a sell rating and four have given a buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Hold" and an average price target of $16.57.

Y-mAbs Therapeutics Stock Down 2.6 %

The stock has a market capitalization of $615.98 million, a price-to-earnings ratio of -28.71 and a beta of 0.74. The company's fifty day simple moving average is $15.54 and its 200 day simple moving average is $9.70.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its earnings results on Thursday, February 29th. The company reported ($0.02) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.17. The company had revenue of $23.36 million during the quarter, compared to analysts' expectations of $21.72 million. Y-mAbs Therapeutics had a negative net margin of 25.26% and a negative return on equity of 20.72%. As a group, analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.43 earnings per share for the current year.

Insider Activity

In other news, SVP Vignesh Rajah sold 1,711 shares of the business's stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $16.53, for a total value of $28,282.83. Following the completion of the sale, the senior vice president now owns 33,889 shares of the company's stock, valued at $560,185.17. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 21.50% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Y-mAbs Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of YMAB. Polar Capital Holdings Plc lifted its position in Y-mAbs Therapeutics by 108.9% during the first quarter. Polar Capital Holdings Plc now owns 2,877,671 shares of the company's stock worth $34,187,000 after purchasing an additional 1,500,000 shares during the period. Millennium Management LLC raised its stake in Y-mAbs Therapeutics by 4,676.0% during the fourth quarter. Millennium Management LLC now owns 1,128,702 shares of the company's stock worth $5,508,000 after acquiring an additional 1,105,069 shares in the last quarter. State Street Corp raised its stake in Y-mAbs Therapeutics by 58.5% during the first quarter. State Street Corp now owns 2,308,782 shares of the company's stock worth $27,428,000 after acquiring an additional 852,112 shares in the last quarter. AQR Capital Management LLC acquired a new position in Y-mAbs Therapeutics during the fourth quarter worth about $2,343,000. Finally, Point72 Asset Management L.P. acquired a new position in Y-mAbs Therapeutics during the fourth quarter worth about $2,193,000. Institutional investors own 70.85% of the company's stock.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.